While clinical response, i.e. shrinkage of the tumour, can be used as the marker of response, most of these studies have used change in the proliferative marker Ki67 as the index of responsiveness9–11 since this has been found to predict benefit from adjuvant endocrine therapy. The gene discussed is MKI67; the disease is neoplasm.